Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Additional preclinical studies provided FDA with reassurance during a second-cycle review that lorcaserin was unlikely to trigger the valvular heart disease associated with dexfenfluramine and fenfluramine.

Advertisement

Related Content

When Opportunity Knocks: Eisai Turns To Business Development
Regulatory Round-Up: Drug Review Profiles From 2012
Regulatory Round-Up: Drug Review Profiles From 2012
FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs
Judging Obesity Drugs: Can Patient-Focused Statistics Bring Simplicity, Clarity?
FDA Clears Belviq With Post Hoc Finding Of Less Than Double Placebo CV Risk
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
FDA Issues Complete Response Letter for Arena's Lorcaserin
Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess
FDA FENFLURAMINE/REDUX EPIDEMIOLOGICAL ANALYSIS OF HMO RECORDS SUPPORTS FINDINGS OF VALVULOPATHY IN ASYMPTOMATIC PATIENTS REPORTED FROM FIVE SURVEYS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel